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Summary 
CD43  (leukosialin,  gpL115,  sialophorin)  is  a  major  sialoglycoprotein widely expressed  on 
hematopoietic cells that is defective in the congenital immunodeficiency  Wiskott-Aldrich syndrome. 
It is thought to play an important role in cell-cell interactions and to be a costimulatory molecule 
for T lymphocyte activation. Using a metabolic 35SO42- radiolabeling assay or biotinylation of 
cell surface proteins,  we describe here that CD43 are sulfated molecules the glycosylation of 
which is altered in human immunodeficiency virus type 1 (HIV-1)-infected leukemic T  cells 
of the CEM line. Hyposialylation of O-glycans and changed substitution on N-acetylgalactosamine 
residues are observed. The glycosylation defect is associated with an impairment of CD43-mediated 
homotypic aggregation which can be restored by resialylation. The hyposialylation of CD43 
on HIV-1 + cells may explain the high prevalence of autoantibodies directed against nonsialylated 
CD43 that have been detected in HIV-l-infected individuals. A defect in glycosylation of important 
molecules such as CD43 or, as we recently described, CD45 may explain alterations of T  cell 
functions and viability in HIV-l-infected individuals.  In addition,  a possible implication of 
hyposialylation in the HIV-l-infected cells entrapment in lymph nodes could be envisioned. 
S 
everal mechanisms have been proposed to explain AIDS 
pathogenesis (reviewed in reference 1). Among them, au- 
toimmunity against lymphocytes and platelets has been ob- 
served. Autoantibodies have been described against several mol- 
ecules  including  the  following:  (a)  a  18-kD  protein  (2) 
expressed in activated lymphocytes; (b) MHC class II (3); (c) 
recombinant CD4 molecules (4); and (d) particular forms of 
CD43 (5).  In the last case, the autoantibodies were found 
to react with partially sialylated CD43 expressed on thymo- 
cytes or in COS cells transfected with a CD43 cDNA (5). 
The CD43 integral membrane glycoprotein is expressed 
on leukocytes and platelets. This molecule is heavily sialylated 
with 70-85 O-linked carbohydrate side chains (6). The elec- 
trophoretic mobility of CD43 on SDS-PAGE has been shown 
to vary from Mr of "~ 115,000 daltons in resting lymphocytes 
and CEM cells (7) to Mr of ",,135,000  daltons in activated 
cells, due to changes in O-glycan biosynthesis (8). Moreover, 
neuraminidase treatment of CD43 molecules could further 
reduce the Mr of CD43 to 150,000 daltons (5, 7, 9). Finally, 
CD43 from activated cells may reach a Mr up to ~172,000 
daltons after sialidase treatment (8). 
CD43 glycoprotein participates in monocyte and T lym- 
phocyte activation as an accessory signaling/activation mole- 
cule (10-13)  and regulates lymphocyte adhesion (14).  Var- 
ious anti-CD43  mAbs have been shown to induce specific 
homotypic aggregation of human T  lymphocytes (11) and 
monocytes (10). 
We recently described an alteration in the sialylation status 
of several T cell surface glycoproteins in HIV-l-infected cells 
of the CEM line and identified CD45 as one of them (15). 
In a latently and a virus-producing HIV-l-infected T CEM 
cell line, up to 75% of the total tyrosine phosphatase activity 
displayed by CD45  molecules were precipitated by peanut 
lectin  (Arachis  hypogaea  [PNA] 1 lectin),  whereas parental 
CEM cells did not exhibit this phenomenon. Since this lectin 
recognizes the terminal Gal~l --~ 3GalNAc disaccharide with 
the restriction that it is not sialylated, a profound defect of sialic 
acid was then demonstrated on these CD45 molecules. In 
this study, nonsialylated glycoproteins with Mr >  105, other 
than CD45, were also detected. Here, we describe that CD43 
is (a) a sulfated molecule in human lymphocytes; (b) differ- 
ently substituted on N-acetylgalactosamine (GalNAc) residues; 
and (c) hyposialylated when it is expressed in HIV-l-infected 
CEM cells. As a likely consequence, HIV-l-positive CEM 
1 Abbreviations used in this paper: a2 ~  3ST, Gal/~l ~  3GalNAcc~2  ~  3 
sialyltransferase  (EC 2.4.99.4); or2 ~  6ST, Galfll ~  4GlcNAcot2 ---- 6 
sialyltransferase  (EC 2.4.99.1); GalNAc,  N-acetylgalactosamine;  GIcNAc, 
N-acetylglucosamine;  NeuNAc,  N-acetylneuraminic  acid; PNA, peanut 
lectin (Arachis hypogaea). 
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This impairment may be corrected by a resialylation proce- 
dure on intact cells. These observations may help to under- 
stand the effects of the HIV-1 virus on the immune system. 
Materials and Methods 
Antibodies and Reagents.  The anti-CD43 mAbs used in this study 
were: DF-T1 (purchased from Dako A/S, Copenhagen, Denmark) 
and 84-3C1 (kindly provided by Dr. J. Vives, Servei d'Immunologia, 
Hospital Clinic i Provincial,  Barcelona, Spain); anti-CD45 mAb 
was 9.4 (obtained from American Type Culture Collection [ATCC], 
Rockville, MD); and control IgG1 mAb was purchased from Dako 
A/S.  The  rabbit  polyclonal  antiserum  raPN/NP  (anti-CD43 
PNA +) was obtained as follows: hyposialylated glycoproteins from 
CEML^I/NP cells were partially purified by affinity chromatog- 
raphy on agarose-immobilized  PNA lectin (E.-Y. Laboratories, Inc., 
San Mateo, CA) which specifically recognizes nonsialylated Gal~l 
3GalNAc disaccharide  (16). Proteins of 170-180 kD were then 
excised from SDS-PAGE gels and injected to New-Zealand/Califor- 
nian hybrid rabbits (Lefebvre, J. C., and V. Giordanego, manuscript 
in preparation).  FITC-PNA lectin was purchased from E.-Y. Labora- 
tories; 2-deoxyglucose from Sigma Chemical Co. (St. Louis, MO); 
and  cytidine-5'-monophospho-9-(3-fluoresceinylthioureido)-9- 
deoxy-N-acetylneuraminic  acid from Boehringer Mannheim GmbH 
Biochemica (Mannheim,  Germany). 
Cells, Cultures, and HIV-1 Strains.  The parental CEM cell line 
(ATCC CCL 119) was maintained in RPMI 1640 medium (GIBCO 
BRL, Gaithersburg, MD) containing 5% FCS (Whittaker M.A. 
Bioproducts, Inc., WalkersviUe, MD), and supplemented with 2 mM 
glutamine, 100 U/ml penicillin, and 50/zg/ml streptomycin. The 
HIV-1 strains  used in this st(xdy are: LAI (BRU) (17), and BCL, 
obtained from H. Fleury (I.aboratoire de Virologie Facult6 de Mrdi- 
cine, Bordeaux, France) (18). After a pretreatment with 2 #g/ml 
hexadimetrine (polybrene), (Sigma Chemical Co.) for 2 d, CEM 
cells were infected by suspending with virus stocks (clarified cul- 
ture supematants concentrated 100-fold by ultracentrifugation). In- 
fected CEM cells (CEMtAI,  CEM~cL) were found to chronically 
produce virus for up to 6 mo without any apparent cytopathicity. 
Infection was documented by the measure of reverse transcriptase 
activity and the evaluation of HIV-1  p24r176  antigen with an an- 
tigen assay (HIV-1 p24; Retrovirology Coulter Co., Hialeah, FL). 
Thereafter, virus production decreased  progressively and finally 
stopped. The absence of spontaneous reactivation of virus produc- 
tion was regularly controlled. The nonproducing HIV-l-infected 
CEM cells were identified by the su~x  "/NP" (CEMrAI/NP). 
Polymerase chain reaction analysis revealed the persistence of HIV-1 
provirus in these cells (not shown). 
Flow Cytometry Analysis.  Immunofluorescence stainings  were 
performed as previously described (15). Stained cells were analyzed 
on a FACScan |  flow cytometer (Becton Dickinson & Co., Moun- 
tain View,  CA). 
3ss042-  Metabolic  Radiolabeling  Assay  and  Immunoprecipita. 
tions.  Cells  (4  x  106/ml) were washed and incubated for 18 h 
in SO42--free RPMI 1640 medium containing 35SO4Z- (ICN Bio- 
medicals,  Inc., Costa Mesa, CA), (1 mCi/ml) and 5% dialyzed 
FCS.  Cells were washed twice and lysed (4  x  106 cells/ml) for 
60 min in lysis buffer containing 50 mM Hepes, pH 8; 1% Nonidet 
P-40, 150 mM NaC1, 10 mM EDTA, I mM EGTA, 1 mM PMSF, 
10 mg/ml aprotinin (both from Sigma Chemical Co.) and 10 mg/ml 
leupeptin (Boehringer-Mannheim GmbH, Biochemica). After cen- 
trifugation of the lysates (18,000 g for 1 h), 2 #g of various mAbs 
were added to 250 #1 supernatant aliquots.  After shaking for 1 h 
at 4~  25 #1 of protein A-Sepharose 4B beads (Sigma Chemical 
Co.) precoated with 10 #g of rabbit anti-mouse Ig were added. 
For immunopredpitations with raPN/NP, 10 #1 of the rabbit serum 
were precoated on protein A-Sepharose 4B beads. After a 2-h agi- 
tation, precipitates were collected by brief centrifugation.  The pellets 
were washed three times in lysis buffer and once with the same 
buffer containing 1 M NaC1. They were resuspended in SDS-PAGE 
sample buffer (2% SDS, 1.7 M 2-ME) and boiled for 3 rain. Samples 
were resolved by SDS-PAGE (7.5% gels). Molecular mass markers 
(GIBCO BILL) were H chain myosin (215.5K) and phosphorylase 
B (105.1K). After intensification with Amplify (Amersham Corp., 
Arlington Heights, IL), the gels were vacuum dried and exposed 
to XAR5  Kodak films. 
Biotinylation of Cell Surface Proteins.  Cell surface proteins were 
biotinylated as previously described  (19).  Briefly, 9  ￿  107 cells 
were suspended in 2.5 ml saline solution containing 25 mM Hepes 
buffer, pH 8, and 1 mg/ml of sulfo-N-hydroxysuccinimide-biotin 
(Pierce Chemical Co., Rockford, IL) for 40 rain at 22~  Reaction 
was stopped by adding 12/~1 of PBS-glycine (0.2 M, pH 7.2). Cells 
were then washed three times and lysed as described above. Pro- 
teins were resolved by SDS-PAGE (5% gels) in a minigel apparatus 
and then transferred to a Hybond-N nylon membrane (Amersham 
Corp). Biotinylated proteins were revealed by reaction with a strep- 
tavidin/horseradish-peroxidase complex (StreptABC Complex/HRP; 
purchased from Dako A/S) according to the manufacturer recom- 
mendations.  The membrane  was  further  incubated  with  elec- 
trochemiluminescence (ECL) Western blotting detection reagents 
(Amersham Corp.) and exposed to XAK5 Kodak film for 2 s to 
1 min. 
Glycosidase Treatments.  When indicated, immune precipitates 
collected on Sepharose beads were treated by either sialidases and/or 
O-glycosidase or ~-galactosidase.  For desialylation,  beads  were 
resuspended with a mixture of 1 mU Vibrio cholerae plus 0.5 mU 
Artkrobacter ureafaciens sialidases (Boehringer Mannheim GmbH Bin- 
chemica) for 3 h at 37~  in 100/zl Tris-HC1 buffer (50 raM, pH 
7.8) containing 1 rnM PMSF and 5 mM CaC12. When indicated, 
for subsequent deglycosylation, beads were washed in lysis buffer 
and  treated  with  1  mU  /~-galactosidase  from  bovine  testes 
(Boehringer Mannheim GmbH Biochemica)  in 100 #1 of sodium 
citrate phosphate buffer (0.1 M, pH 4.3) containing 1% BSA (Sigma 
Chemical  Co.)  and  10%  glycerol  (vol/vol)  or  with  1  mU 
endo-c~-N-acetyl-o-galactosaminidase (O-glycosidase), (EC 3.2.1.97) 
from Diptococcus pneumoniae (Boehringer Mannheim GmbH Bin- 
chemica) in 100 #1 sodium cacodylate buffer (20 raM, pH 6) con- 
taining 1 mM PMSF,  1% Triton X-100,  and 0.1% SDS for 3 h 
(or 18 h in some other experiments) at 37~  Desialylation of cells 
was carried out by incubation (106 cells/100 #l) with the mixture 
of I mU V. cholerae plus 0.5 mU A. ureafaciens sialidases for 1 h 
at 37~  in PBS with gentle shaking. 
Resiatytation.  CD43-coated beads were treated by 0.3 mU Gal~l 
--~ 3GalNAc cr  --~ 3Sialyltransferase (EC 2.4.99.4), (o~2 -~ 3ST), 
(Boehringer Mannheim GmbH Biochemica) in 100 #1 Mes-NaOH 
buffer (50 raM, pH 6.1) containing 100 mM cytidine-5'-mono- 
phospho-N-acetylneuraminic acid  (CMP-NeuNAc)  (Boehringer 
Mannheim GmbH Biochemica), 0.1% BSA, 1 mM PMSF, and 0.5% 
Triton X-100  for 3  h  at 37~  For resialylation  of intact cells, 
2  x  106 cells were suspended  in 100 #1 PBS containing 20 mM 
cytidine-5'-monophospho-9-(3-fluoresceinylthioureido)-9-deoxy- 
N-acetylneuraminic acid and 0.25 mU of or2 -~ 3ST (Boehringer 
Mannheim  GmbH Biochemica)  and gently shaken  at 37~  for 
15 min. Cells were then tested for specific mAb aggregation. For 
resialylation  controls, after four washes with PBS, cells were fixed 
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Cell Aggregation.  Cells  (5  ￿  105/ml) were suspended  in RPMI 
1640 medium with 5% FCS containing 1 /xg/ml various mAbs 
or Ig controls and incubated for 20 min at 37~  before plating 
in fiat-bottomed microtiter plates (100/~l/well). Cells were then 
incubated at 37~  in 7% CO2 in a humidified incubator for 4 h. 
Thereafter, cells  were gently shaken  by micropipetting. Cell layers 
were photographed after additional 1-h incubation period. 
Results 
Lymphocyte CD43 Molecules Are Sulfated and Modified in HIV- 
1-infected  CEM  Cells.  To study possible  modifications of 
CD43  molecules in  HIV-l-infected CEM  ceils,  we  used 
different labeling methods. A  sulforadiolabeling technique 
appeared  to be more sensitive,  since a 5-h exposure of the 
gel gave similar results as a several day exposure  in the case 
of  [3SS]methionine  labeling  (not  shown).  After  35S042- 
metabolic radiolabeling, immunoprecipitations were carried 
out with the anti-CD43 mAb DF-T1. As shown on Fig.  1, 
a  and b,  CD43  molecules appeared  as a 115-120-kD  band 
in parental CEM cells (Fig. 1 a, lane 3) and in PHA-activated 
PBL, (Fig.  1 b, lane 3);  while those from CEMLAI/NP as 
a heterogeneous 160-170-kD band (Fig.  I a, lane 7). CD43 
from CEMBcL that are productively HIV-l-infected showed 
two bands, one at 115-120 kD and the other broad band at 
135-160 kD (Fig. 1 a, lane 6). Another anti-CD43 mAb 84- 
3C1 (9) gave the same results (Fig.  1 a, lanes 2, 4, and 5). 
Since the differences in CD43 mobility that we observed 
in CEMLAI/NP with Mr of 160,000-170,000  daltons were 
close to those described after neuraminidase treatment of CD43 
from activated lymphocytes (Mr of "172,000  daltons), (8), 
we hypothesized that HIV-l-infected CEM cells expressed 
hyposialylated CD43  molecules. 
Because CD43 from CEMLAI/NP (Fig.  1 a, lanes 5 and 
7) were revealed to a lesser degree than those immunoprecip- 
itated from parental CEM (Fig.  1 a, lanes 2 and 3) or from 
CEMBcL (Fig.  1 a,  lanes  4  and 6),  we developed  a rabbit 
polyclonal antiserum against these hypothetical hyposialylated 
CD43.  A  hybrid New Zealand/Californian rabbit was im- 
munized with SDS-PAGE semipurified 170-180-kD  glyco- 
proteins previously precipitated by immobilized PNA lectin 
from CEMLAI/NP lysates.  By the sulforadiolabeling assay, 
the antiserum (raPN/NP)  could precipitate the upper and 
lower CD43 bands with much more effidency  than anti-CD43 
mAbs  (Fig.  1 a,  lanes  9,  11,  and  12).  The  reactivity of 
raPN/NP toward CD43 was confirmed by Western blotting 
assay: CD43  previously immunoprecipitated from parental 
CEM and CEMLAI/NP, by the raPN/NP antiserum, or by 
anti-CD43 mAb DF-T1  and transferred onto nylon mem- 
brane were equally detected by DF-T1 (not shown). It has 
to be pointed out that the raPN/NP serum recognizes 115-120- 
kD CD43 forms from parental CEM cells while immuniza- 
tion was performed with 170-180-kD  glycoproteins from 
CEMLAJNP cells. Thus, this antiserum recognizes different 
forms of the same CD43 glycoprotein that are differentially 
sialylated as we demonstrate below. The raPN/NP antiserum 
also recognized 180-190-kD  CD45 molecules in the Western 
blotting assay (not shown). CD45 appeared also as a charac- 
teristic 180-190-kD doublet immunoprecipitated  by raPN/NP 
in the sulforadiolabeling assay from CEM cells (Fig. 1 a, lane 
9) and from PBL (Fig.  1 b, lane 2), indicating that CD45 
molecules from these two cell species are also sulfated (Lefebvre, 
J.-C., unpublished observations). 
Modified  CD43  Molecules from  HIV-l-infected  CEM Cells 
Are Partially  Sialylated.  As shown by others (7, 9, 20, 21), 
treatment of CD43 molecules from parental CEM cells with 
sialidases induced a dramatic reduction in their electrophoretic 
mobility (Fig. 2 a, lanes 3 and 4). CD43 from CEMLAI/NP 
showed also an additional reduction in their mobility upon 
Figure  1.  Variations  in electrophoretic  mobility  of 35SO42--labeled CD43 molecules. Immunoprecipitations  were carried out from parental CEM 
cells (lanes 1-3, 8-9), virus-producing  (CEMBcL;  lanes  4, 6, 10, and 11) or latently  HIV-l-infected  (CEMLAt/NP,  lanes 5, 7, and 12) CEM cells, with 
anti-CD43 mAbs DF-T1 (lanes 3, 6 and 7), 84-3C1 (lanes 2, 4, and 5), or with the polyclonal  rabbit serum raPN/NP (lanes  9, 11, and 12). A control 
irrelevant IgG1 mAb was used in lane I and a preimmune  rabbit serum in lanes 8 and 10. (b) Variations  in electrophoretic  mobility  of 3sSO42--labeled 
CD43 molecules.  Immunoprecipitations  were  carried out from normal  PHA-activated  PBLs. The rabbit polyclonal  raPN/NP serum (lane  2) recognized 
CD43 and the 180-190-kD doublet  CD45. The controls were: anti-CD45 mAb 9.4 (lane I), anti-CD43 mAb DF-T1 (lane  3), and preimmune  rabbit 
serum (lane 4). 
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immunoprecipitated by the rabbit raPN/NP serum after metabolic sul- 
foradiolabeling from parental CEM (lanes 1 and 2), HIV-l-infected virus 
producing  CEMacr  (lanes 3  and  4)  and  from  virus nonproducing 
CEMr^I/NP  (lanes 5 and 6).  Before gel resolution, coated beads were 
treated by c~2 --* 3ST (lanes I, 3, and 5) or left untreated (lanes  2, 4, and 6). 
Figure  2.  (a) Desialylation of CD43 molecules. After metabolic sul- 
foradiolabeling, CD43 was immunoprecipitated from lysates of parental 
CEM cells (lanes 1--4) and CEMtAI/NP (lanes 5-8) by DF-T1 mAb (lanes 
I, 4, 5, and 8) or by the polyclonal rabbit raPN/NP serum (lanes 2, 3, 
6, and 7) and treated by sialidases (lanes 3, 4, 7, and 8) or left untreated 
(lanes I, 2, 5, and 6). (b) Immunoprecipitation and desialylation of cell 
surface biotin-labeled CD43 molecules. CD43 were immunoprecipitated 
from CEM cells (lanes 1-3), CEML^~/NP (lanes 4 and 5) by DF-T1 mAb. 
Control was an irrelevant IgG1 mAb. Coated beads were treated by a mix 
of sialidases (lanes 2 and 5) or left untreated (lanes 1 and 4). 
sialidases treatment (Fig. 2 a, lanes 7 and 8). The desialylated 
CD43  molecules  treated  by  neuraminidases  were  more 
efficiently precipitated by raPN/NP  (Fig.  2  a,  lanes 3  and 
7) than by the DF-T1 mAb (Fig. 2 a, lanes 4 and 8). To fur- 
ther demonstrate that CD43 molecules from HIV-l-infected 
CEM cells were only partially sialylated we used a resialyla- 
tion procedure.  Treatment of CD43  from CEMr^I/NP  and 
CEMBcL with a2 --* 3ST (EC 2.4.99.4),  (22) gave a partial 
restoration of their electrophoretic mobility (Fig. 3, lanes 3 
and  5),  while  CD43  from  parental  CEM  cells  were  not 
modified by  this  treatment  (Fig.  3,  lane  I). 
Hyposialylated CD43 Molecules Are Efficiently  Transported to 
the Cell Surface.  Cell surface proteins were biotinylated on 
intact  cells  and  immunoprecipitated  from  cell  lysates  by 
raPN/NP.  This biotinylation assay,  which  is not restricted 
to sulfated molecules, showed that electrophoretic mobility 
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of CD43 from CEML^I/NP  (a) was reduced (Fig. 2  b, lane 
4) as compared with CD43 from parental CEM cells CD43 
(Fig. 2 b, lane 1); (b) can be further reduced by sialidase treat- 
ment (Fig. 2 b, lane 5), demonstrating  at least some degree 
of  sialylation;  (c)  was  also  reduced  as  compared  with  in 
vitro-desialylated CD43 from parental CEM cells (Fig. 2 b, 
lane 2),  indicating  that  hyposialylation  is  not  sufficient to 
explain the  significant  difference in  gel migration between 
parental  CEM  and  CEMLAx/NP cell CD43,  the glycosyla- 
tion  of which  is  likely more complex. 
Hyposialylated CD43 Molecules  from HIV-l-infected Cells Bear 
More Complex O-glycans.  We next tried to deglycosylate by 
endo-oL-N-acetyl-D-galactosaminidase (O-glycosidase) treat- 
ment, (EC 3.2.1.97), CD43 molecules. This enzyme is known 
to hydrolyze the or-linkage between disaccharide Gal-GalNAc 
from its serine or threonine moiety with the restriction that 
it is not substituted by any sialic acid or fucose or N-acetyl- 
glucosamine  (GlcNAc)  residue  (23).  As  shown  on  Fig.  4, 
Figure 4.  Deglycosylation  of CD43. After metabolic  sulforadiolabeling, 
combined enzymatic treatment (sialidases,/3-galactosidase,  and O-glyco- 
sidase) was performed on beads coated with CD43 molecules immuno- 
precipitated by the rabbit polyclonal  raPN/NP serum from lysates of pa- 
rental CEM cells (lanes 1-3, 7-9) and HIV-l-infected virus nonproducing 
CEMt^I/NP (4-6, 10-12). Before  deglycosylation,  coated beads were pre- 
viously treated with a mix of sialidases (lanes 1-6) or nontreated (lanes 
7-12). Thereafter, beads were washed in lysis buffer and directly denatu- 
rated for resolution by SDS-PAGE  7.5% (lanes 1, 4, 7, and I0) or treated 
by B-galactosidase (lanes 2, 5, 8, and I1)  or by O-glycosidase (lanes 3, 
6, 9, and 12). 
in HIV-l-infected CEM Cells deglycosylation  by O-glycosidase was effective on CD43 from 
parental CEM, only after a pretreatment with sialidases (Fig. 
4, lane 3).  In contrast, deglycosylation of CD43 molecules 
from CEMLAI/NP was not possible even after a preincuba- 
tion with sialidases (Fig.  4, lane 6).  The variation in elec- 
trophoretic mobility of sialidase- and O-glycosidase-treated 
CD43 from parental CEM cells appears to be very weak, how- 
ever it is significant and comparable with that described by 
Ardman et  al.  (5).  Moreover, the absence  of variation of 
CEMLAJNP cell CD43  treated under the same conditions 
suggests that these molecules have a more complex carbohy- 
drate structure than parental CEM cell CD43. As a control, 
hydrolysis of galactoses by ~-galactosidase from bovine testes, 
which splits terminal galactoses from Gal/81 --- GalNAc, Gal~l 
-"  4GlcNAc,  and  GalB1  -*  3GlcNAc,  was  not  observed 
through an electrophoretic mobility shift, even after desialy- 
lation (Fig. 4, lanes 2, 5, 8, and II). After labeling of galac- 
tose residues by the galactose oxidase/tritiated sodium boro- 
hydride reduction method (24),  the enzymatic activity of 
/~-galactosidase  was  verified  by  a  significant  release  of 
[3H]NaBH4  galactose residues (not  shown). Therefore the 
observation that removal of galactose residues by ~-galac- 
tosidase treatment did not affect CD43 electrophoretic mo- 
bility highlights (a) the slight variation induced by O-glyco- 
sidase treatment of CEM cell CD43; and (b) the absence in 
variation of CEMLAI/NP cell CD43 treated under the same 
conditions. 
Hyposialylated  Lymphocytes  Are  Not  Found  in  PBLs  of 
HIV +  Individuals.  Using  FITC-PNA  lectin,  we  have 
screened resting and PHA-activated PBL from fifteen HIV § 
individuals. This lectin is specific for Gal/81 --- 3GalNAc di- 
saccharide,  branched on O-glycan with the restriction that 
it is not sialylated (16).  As shown on Fig.  5,  we have de- 
scribed a strong reactivity of this lectin against CEMr^JNP 
cells (Figs. 5 a, histogram 12; 5 b, histogram 2), (15) by con- 
trast to CEM cells which are almost unreactive (Figs.  5 a, 
histogram 4; 5 b, histogram 1). In accordance with an earlier 
report, we failed to find any hyposialylated circulating lym- 
phocytes in HIV + individuals (Fig.  5 b, histogram 4) as in 
noninfected individuals (Fig.  5 b,  histogram 3),  (5). 
Hyposialylated CD43 Molecules Are Recognized by Neuramin- 
idase Sensitive  mAbs  at  the Surface of HIV-l-infected  CEM 
Cells.  As shown above,  partially sialylated CD43 may be 
immunoprecipitated from HIV-l-infected CEM cells by the 
mAbs DF-T1 and 84-3C1, and these molecules are efficiently 
transported to the cell surface.  Using immunofluorescence 
staining, we confirmed that the mAbs were able to recog- 
nize intact parental CEM  (Fig.  5 a,  histograms 2  and 3), 
CEMLAI/NP (Fig. 5 a, histograms 10 and 11), and CEMBcL 
cells (Fig.  5 a, histograms 18 and 19). The binding of anti- 
CD43 DF~T1 and 84-3C1 mAbs appeared to be slightly lower 
in HIV-l-infected CEM cells. As shown on Fig. 5 a, removal 
of sialic acids by treatment of the cells with sialidases com- 
pletely abolished the binding of DF-T1 and 84-3C1  mAbs 
to  parental  CEM,  CEMLAI/NP,  and  CEMBcL (Fig.  5  a, 
histograms 6, 7, 14, 15, 22, and 23), as compared with flow 
cytometry profiles obtained with  an irrelevant IgG1  mAb 
(Fig. 5 a, histograms I, 9, and 17). These results are in agree- 
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ment with the previously reported sensitivity of the anti-CD43 
mAbs to neuraminidase treatment (9, 25). Our results showed 
hyposialylated CD43  from  CEMLAI/NP  or  CEMBcL are 
nevertheless significantly recognized by DF-T1 and 84-3C1 
mAbs. 
Impairment of CD43-mediated Homotypic Aggregation Of  HIV- 
1-infected CEM Cells.  The CD43 DF-T1 mAb was able to 
induce in parental CEM cells an homotypic aggregation (Fig. 
6,  panel 2).  It is known that this phenomenon is not due 
to a simple cross-linking of cells by antibodies but an active 
process (26, 27). We then verified that CD43-mediated aggre- 
gation we observed was inhibited by metabolic poisons. Ad- 
dition of 0.2% azide plus 5 mM 2-deoxyglucose completely 
abolished cell-cell adhesion. Moreover, irrelevant IgG1 or anti 
CD45 9.4 mAb did not induce CEM cells aggregation (not 
shown). This specific homotypic cell adhesion was not ob- 
served with HIV-l-infected CEMBcL or CEMLM/NP cells 
(Fig. 6, panel 5). Intact CEMLAI/NP  and CEMBcL cells were 
then resialylated with fluorescent precursor NeuNAc by or2 
3ST. As shown in Fig. 5 c (histograms 1 and 2), the fluores- 
cence associated  with neuraminic acid was detected at the 
surface of treated cells, thus demonstrating that resialylation 
was efficient. R.esialylation was able to correct the defect in 
homoaggregates formation induced by CD43 mAb (Fig. 6, 
panel 6). Similar results were obtained with the 84-3C1 mAb 
(not shown). 
Discussion 
In this paper,  we describe a reduction in electrophoretic 
mobility of CD43 molecules in HIV-l-infected CEM ceils. 
This modification of CD43 can not be due to alternative exon 
splicing since the molecule is known to be the product of 
a single coding exon (28) of a single gene (29). Earlier reports 
have shown that a change in O-glycan biosynthesis leading 
to a hexasaccharide substitution on CD43 from activated lym- 
phocytes, instead of a tetrasaccharide as in CD43 from resting 
T  cells  leads  to  a  shift  of CD43  Mr  from  -,115,000  to 
135,000 daltons by SDS-PAGE (8). Moreover, neuraminidase 
treatment of immunoprecipitated CD43 induced an even more 
dramatic change (5, 7, 9) to a Mr of •  150,000 daltons (7). 
The modifications we observed on CD43 molecules (Mr of 
~160,000-170,000  daltons) immunoprecipitated from virus 
producing or latently HIV-l-infected CEM cells are reminis- 
cent of those described after in vitro desialylation of CD43 
molecules from activated lymphocytes (8).  In the last case, 
changes in O-glycan biosynthesis together with sialidase treat- 
ment gave CD43 molecules with Mr of 172,000 (8). More- 
over, CD43 glycoproteins from CEML^I/NP cells could be 
further desialylated in vitro,  thus demonstrating some de- 
gree of sialylation. 
Significant resialylation of CD43 was obtained with or2 
3ST, which links a NeuNAc moiety to Gal~l --~ 3GalNAc 
disaccharide attached to Ser/Thr amino acids in O-linkage. 
Similar observations were made on CD45 from CEMLAI/NP 
(15). Resialylation of these CD45 molecules was obtained 
by or2 --* 3ST and Gal31 ~  4GlcNAc 6 sialyltransferase  (EC 
2.4.99.1)  (or2 --* 6ST) demonstrating that several glycopro- IgG1  84-3C1  DF-T1  PNA 
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Figure  5.  Flow cytometry analysis of 
membrane proteins. (a) The following 
cells were tested: parental CEM (histo- 
grams  1-8),  nonproducing  HIV-1- 
infected CEM  cells  (CEMtAi/NP  or 
histograms 9-I6) and virus-producing 
HIV-l-infected CEM  cells  (CEMBcL 
or histograms 17-24), with or without 
previous sialidase treatment as indicated. 
Cells were stained with 2/+g anti-CD43 
84-3C1  (histograms 2,  6,  10,  14,  18, 
and 22), or DF-T1 (histograms 3, 7, 11, 
15,  19,  and 23)  mAbs or FITC-PNA 
lectin (1 #g PNA/ml), (histograms 4, 
8, 12, 16, 20, and 24), control was an 
irrelevant IgG1 mAb (histograms I, 5, 
9,  13,  I7,  and 21).  (b) The reactivity 
of FITC-PNA lectin (1 #g PNA/ml) 
was tested towards parental CEM (histo- 
gram 1)  or CEMLAI/NP cells  (histo- 
gram 2)  or PBLs  from an HIV + in- 
dividual (histogram 4).  Control was 
PBLs  from  a  noninfected individual 
(histogram 3). (c) CEMLAI/NP (histo- 
gram I) and CEMBct cells (histogram 
2)  were  resialylated  by fluoresceinyl- 
sialic acid attached by ~2~3ST. Con- 
trols were nonstained nonresialylated 
CEMLAI/NP  (histogram  I')  and 
CEMBcL (histogram 2'). The fluores- 
cence intensity of 105 cells  was  ana- 
lyzed on a FACScan  | 
1614  Altered Glycosylation of CD43 in HIV-l-infected CEM Cells Figure  6.  Homotypic  aggregation  of CEM cells. Parental CEM cells 
(panels 1, 2, and 3) and latently  HIV-l-infected  CEMLAI/NP  (panels 4, 
5, and 6) were incubated  with control  irrelevant  IgG1 mAb (panels I and 
4) or anti-CD43 DF-T1 (panels 2 and 5) or previously  resialylated  with 
c~2~3ST (panels 3 and 6) before incubating  with DF-T1 mAb. 
teins from HIV-l-infected CEM cells were hyposialylated on 
O- and N-linked carbohydrate side chains. Since all the known 
sialyltransferases  are located in the trans-Gol~, the partial sialy- 
lation of CD43  molecules could not be due to a defective 
trafficking of the molecules inside the cell. 
As described for murine CD43 (30), we also showed that 
lymphocyte  CD43 molecules are sulfated in human CEM cells 
and activated human PBL. CD43 sulfation might be of im- 
portance for ligand-receptor interactions since SO42- ions 
have  been  shown  to  be  involved  in  various  recognition 
phenomena (31-34) and required for the binding of GlyCAM- 
i  to L-selectin (35). 
The hyposialylation of CD43  in HIV § cells is reminis- 
cent  of the  defect affecting CD43  in  the  congenital im- 
munodeficiency Wiskott-Aldrich syndrome. In this syndrome, 
CD43 molecules are either defective or have a reduced mi- 
gration in SDS-PAGE.  It has been proposed that they are 
affected by a desialylation process  (7,  36, 37) or by a more 
complex modification of O-glycans induced by an increased 
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activity of 31  ~  6-N-acetylglucosaminyltransferase which 
links a GlcNAc31 ~  6- (with subsequent elongation by a 
NeuNAcoe2  --* 3Gal31 --* 4-)  instead of a NeuNAcot2 
6- to GalNAc attached to Ser/Thr of CD43 in normal lym- 
phocytes (38,  39). 
We have demonstrated that CD43 molecules from HIV- 
1-infected CEM cells were not only partially sialylated but 
also differently substituted on their Gal31 -'* 3GalNAc dis- 
accharides since deglycosylation of CD43 from these cells by 
O-glycosidase was without effect. Moreover,  since resialyla- 
tion was possible  on terminal Gal with an a2 --* 3 linkage 
(Fig.  3,  lanes 3  and 5),  the inactivity of O-glycosidase on 
CD43 from CEMLAI/NP is certainly due to a substitution 
on penultimate GalNAc moieties rather than on terminal Gal 
residues. 
Using restoration of CD43  expression  in negative cells, 
Manjunath et al.  (14) have demonstrated that CD43 inter- 
feres with T  lymphocyte adhesion. CD43-mediated homo- 
typic aggregation has been extensively described (10, 11, 14, 
26,  27,  40). 
Our observations suggest that HIV-1 may alter CD43 func- 
tions through modification of the sialylation status of the 
molecule. Sialic acid residues are thought to play a major role 
in cell-cell interactions. In particular, sialic acid requirement 
has been shown for the recognition of their counter struc- 
tures by selectins (41-47),  or CD22 ligand-receptor interac- 
tions (48-50). 
There is an apparent discordance between the sialic acid 
requirement of CD43-mediated homotypic aggregate forma- 
tion  and  the  enhanced  adhesion  demonstrated in  CD43- 
deficient CEM cells (14) where it was proposed that elec- 
tronegative charges of numerous sialic acid residues attached 
to CD43 serve to repulse CD43 + cells, and thus act to limit 
cell-cell adhesion (51). However, we favor the idea that auto- 
aggregability of modified CD43-deficient  CEM cells  is  a 
phenomenon entirely different from homotypic aggregation 
induced by anti-CD43 activation which requires integrity of 
CD43  molecules. 
Autoimmunity against  hyposialylated CD43  has  been 
demonstrated with a high prevalence in HIV-l-infected in- 
dividuals (5). Modified CD43 molecules responsible  for this 
reactivity were found on normal thymocytes but not on pe- 
ripheral blood lymphocytes of normal donors (52) or HIV- 
1-seropositive individuals (5).  The authors suggested that 
hyposialylated CD43 molecules were provided by an increased 
destruction of lymphocytes in HIV + individuals. Our data 
suggest that hyposialylated CD43 molecules in HIV § cells 
may be responsible for the generation of autoantibodies. Similar 
to Ardman et al. (5), we did not find partially sialylated CD43 
on peripheral  blood lymphocytes of HIV + individuals.  This 
could be due to the low percentage of hyposialylated lym- 
phocytes in the peripheral blood of HIV § individuals and/or 
their trapping in lymph nodes. (Indeed, as a preliminary re- 
port,  we have observed  that-2-5%  of lymphocytes from 
lymph nodes from two HIV § individuals were reactive with 
the PNA lectin specific for Gal-GalNAc disaccharides.) Using 
neuraminidase treatment of rat lymphocytes, it has been shown 
that  sialylated  molecules  play  an  important  role  in  the trafficking of the cells between the different lymphoid sites. 
The desialylated lymphocytes are removed from the circula- 
tion to be initially trapped in the rat liver and subsequently 
emigrate to the lymph nodes where they concentrate (53, 
54). Together with CD45, CD43 represents 38% of the total 
T lymphocyte surface glycoproteins (55). The altered sialyla- 
tion of these two glycoproteins in HIV-l-infected ceils may 
contribute to the observed phenomenon of entrapment of 
HIV + cells in lymph nodes (56). The low percentage of cells 
bearing hyposialylated CD43  may be compensated by the 
strong immunogenicity of carbohydrate antigens (57) to ex- 
plain the generation of autoimmunity. 
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